The UK and US have concluded a key bilateral deal that will guarantee no duties on UK pharmaceutical exports going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This commitment guarantees that duties on these vital exports will remain at nothing for a duration of 36 months.
This deal is in response to recent statements to dramatically increase duties on patented drug imports, with increases discussed as high as 100%.
"This arrangement between the Britain strengthens the international landscape for cutting-edge drugs and introduces long-overdue balance to American-British pharmaceutical trade," a statement noted.
Economic Impact
Drugs constitute one of the Britain's largest goods shipped to the America, which is easily the primary destination for large British pharmaceutical firms.
Trade data reveal that in the 12 months to the end of the third quarter, the UK exported drugs totaling £11.1bn to the US. This figure represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects work, stimulates investment and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister commented.
Specific UK Commitments
The pact involves several key pledges from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to double overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. Previously, refunds exceeded twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the drug companies and the ministers over drug pricing and regulatory access.
This friction were intensified by claims that American patients were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been paused or abandoned, while major investments have been directed toward American operations.
A senior figure stated that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
